Magnetic resonance imaging markers of Parkinsons disease nigrostriatal signature
Identifieur interne : 000102 ( Main/Corpus ); précédent : 000101; suivant : 000103Magnetic resonance imaging markers of Parkinsons disease nigrostriatal signature
Auteurs : Patrice Pran ; Andrea Cherubini ; Francesca Assogna ; Fabrizio Piras ; Carlo Quattrocchi ; Antonella Peppe ; Pierre Celsis ; Olivier Rascol ; Jean-Franois Dmonet ; Alessandro Stefani ; Mariangela Pierantozzi ; Francesco Ernesto Pontieri ; Carlo Caltagirone ; Gianfranco Spalletta ; Umberto SabatiniSource :
- Brain [ 0006-8950 ] ; 2010-11.
Abstract
One objective of modern neuroimaging is to identify markers that can aid in diagnosis, disease progression monitoring and long-term drug impact analysis. In this study, Parkinson-associated physiopathological modifications were characterized in six subcortical structures by simultaneously measuring quantitative magnetic resonance parameters sensitive to complementary tissue characteristics (i.e. volume atrophy, iron deposition and microstructural damage). Thirty patients with Parkinsons disease and 22 control subjects underwent 3-T magnetic resonance imaging with T2-weighted, whole-brain T1-weighted and diffusion tensor imaging scans. The mean R2 value, mean diffusivity and fractional anisotropy in the pallidum, putamen, caudate nucleus, thalamus, substantia nigra and red nucleus were compared between patients with Parkinsons disease and control subjects. Comparisons were also performed using voxel-based analysis of R2, mean diffusivity and fractional anisotropy maps to determine which subregion of the basal ganglia showed the greater difference for each parameter. Averages of each subregion were then used in a logistic regression analysis. Compared with control subjects, patients with Parkinsons disease displayed significantly higher R2 values in the substantia nigra, lower fractional anisotropy values in the substantia nigra and thalamus, and higher mean diffusivity values in the thalamus. Voxel-based analyses confirmed these results and, in addition, showed a significant difference in the mean diffusivity in the striatum. The combination of three markers was sufficient to obtain a 95 global accuracy (area under the receiver operating characteristic curve) for discriminating patients with Parkinsons disease from controls. The markers comprising discriminating combinations were R2 in the substantia nigra, fractional anisotropy in the substantia nigra and mean diffusivity in the putamen or caudate nucleus. Remarkably, the predictive markers involved the nigrostriatal structures that characterize Parkinsons physiopathology. Furthermore, highly discriminating combinations included markers from three different magnetic resonance parameters (R2, mean diffusivity and fractional anisotropy). These findings demonstrate that multimodal magnetic resonance imaging of subcortical grey matter structures is useful for the evaluation of Parkinsons disease and, possibly, of other subcortical pathologies.
Url:
DOI: 10.1093/brain/awq212
Links to Exploration step
ISTEX:E65855DBDDC436C3433EAECE51000AC6182CDE76Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Magnetic resonance imaging markers of Parkinsons disease nigrostriatal signature</title><author><name sortKey="Pran, Patrice" sort="Pran, Patrice" uniqKey="Pran P" first="Patrice" last="Pran">Patrice Pran</name><affiliation><mods:affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: p.peran@hsantalucia.it</mods:affiliation></affiliation></author><author><name sortKey="Cherubini, Andrea" sort="Cherubini, Andrea" uniqKey="Cherubini A" first="Andrea" last="Cherubini">Andrea Cherubini</name><affiliation><mods:affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Assogna, Francesca" sort="Assogna, Francesca" uniqKey="Assogna F" first="Francesca" last="Assogna">Francesca Assogna</name><affiliation><mods:affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Piras, Fabrizio" sort="Piras, Fabrizio" uniqKey="Piras F" first="Fabrizio" last="Piras">Fabrizio Piras</name><affiliation><mods:affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Quattrocchi, Carlo" sort="Quattrocchi, Carlo" uniqKey="Quattrocchi C" first="Carlo" last="Quattrocchi">Carlo Quattrocchi</name><affiliation><mods:affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Peppe, Antonella" sort="Peppe, Antonella" uniqKey="Peppe A" first="Antonella" last="Peppe">Antonella Peppe</name><affiliation><mods:affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Celsis, Pierre" sort="Celsis, Pierre" uniqKey="Celsis P" first="Pierre" last="Celsis">Pierre Celsis</name><affiliation><mods:affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>4 Clinical Investigation Centre (INSERM CIC-9302) and Department of Neurosciences, University Hospital and University of Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Dmonet, Jean Franois" sort="Dmonet, Jean Franois" uniqKey="Dmonet J" first="Jean-Franois" last="Dmonet">Jean-Franois Dmonet</name><affiliation><mods:affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Stefani, Alessandro" sort="Stefani, Alessandro" uniqKey="Stefani A" first="Alessandro" last="Stefani">Alessandro Stefani</name><affiliation><mods:affiliation>5 Department of Neuroscience, Tor Vergata University, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pierantozzi, Mariangela" sort="Pierantozzi, Mariangela" uniqKey="Pierantozzi M" first="Mariangela" last="Pierantozzi">Mariangela Pierantozzi</name><affiliation><mods:affiliation>5 Department of Neuroscience, Tor Vergata University, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pontieri, Francesco Ernesto" sort="Pontieri, Francesco Ernesto" uniqKey="Pontieri F" first="Francesco Ernesto" last="Pontieri">Francesco Ernesto Pontieri</name><affiliation><mods:affiliation>6 Sapienza University, Second Faculty of Medicine, Department of Neurology, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Caltagirone, Carlo" sort="Caltagirone, Carlo" uniqKey="Caltagirone C" first="Carlo" last="Caltagirone">Carlo Caltagirone</name><affiliation><mods:affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Spalletta, Gianfranco" sort="Spalletta, Gianfranco" uniqKey="Spalletta G" first="Gianfranco" last="Spalletta">Gianfranco Spalletta</name><affiliation><mods:affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Sabatini, Umberto" sort="Sabatini, Umberto" uniqKey="Sabatini U" first="Umberto" last="Sabatini">Umberto Sabatini</name><affiliation><mods:affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E65855DBDDC436C3433EAECE51000AC6182CDE76</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1093/brain/awq212</idno><idno type="url">https://api.istex.fr/document/E65855DBDDC436C3433EAECE51000AC6182CDE76/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000102</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Magnetic resonance imaging markers of Parkinsons disease nigrostriatal signature</title><author><name sortKey="Pran, Patrice" sort="Pran, Patrice" uniqKey="Pran P" first="Patrice" last="Pran">Patrice Pran</name><affiliation><mods:affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: p.peran@hsantalucia.it</mods:affiliation></affiliation></author><author><name sortKey="Cherubini, Andrea" sort="Cherubini, Andrea" uniqKey="Cherubini A" first="Andrea" last="Cherubini">Andrea Cherubini</name><affiliation><mods:affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Assogna, Francesca" sort="Assogna, Francesca" uniqKey="Assogna F" first="Francesca" last="Assogna">Francesca Assogna</name><affiliation><mods:affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Piras, Fabrizio" sort="Piras, Fabrizio" uniqKey="Piras F" first="Fabrizio" last="Piras">Fabrizio Piras</name><affiliation><mods:affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Quattrocchi, Carlo" sort="Quattrocchi, Carlo" uniqKey="Quattrocchi C" first="Carlo" last="Quattrocchi">Carlo Quattrocchi</name><affiliation><mods:affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Peppe, Antonella" sort="Peppe, Antonella" uniqKey="Peppe A" first="Antonella" last="Peppe">Antonella Peppe</name><affiliation><mods:affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Celsis, Pierre" sort="Celsis, Pierre" uniqKey="Celsis P" first="Pierre" last="Celsis">Pierre Celsis</name><affiliation><mods:affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>4 Clinical Investigation Centre (INSERM CIC-9302) and Department of Neurosciences, University Hospital and University of Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Dmonet, Jean Franois" sort="Dmonet, Jean Franois" uniqKey="Dmonet J" first="Jean-Franois" last="Dmonet">Jean-Franois Dmonet</name><affiliation><mods:affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Stefani, Alessandro" sort="Stefani, Alessandro" uniqKey="Stefani A" first="Alessandro" last="Stefani">Alessandro Stefani</name><affiliation><mods:affiliation>5 Department of Neuroscience, Tor Vergata University, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pierantozzi, Mariangela" sort="Pierantozzi, Mariangela" uniqKey="Pierantozzi M" first="Mariangela" last="Pierantozzi">Mariangela Pierantozzi</name><affiliation><mods:affiliation>5 Department of Neuroscience, Tor Vergata University, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pontieri, Francesco Ernesto" sort="Pontieri, Francesco Ernesto" uniqKey="Pontieri F" first="Francesco Ernesto" last="Pontieri">Francesco Ernesto Pontieri</name><affiliation><mods:affiliation>6 Sapienza University, Second Faculty of Medicine, Department of Neurology, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Caltagirone, Carlo" sort="Caltagirone, Carlo" uniqKey="Caltagirone C" first="Carlo" last="Caltagirone">Carlo Caltagirone</name><affiliation><mods:affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Spalletta, Gianfranco" sort="Spalletta, Gianfranco" uniqKey="Spalletta G" first="Gianfranco" last="Spalletta">Gianfranco Spalletta</name><affiliation><mods:affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Sabatini, Umberto" sort="Sabatini, Umberto" uniqKey="Sabatini U" first="Umberto" last="Sabatini">Umberto Sabatini</name><affiliation><mods:affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain</title><idno type="ISSN">0006-8950</idno><idno type="eISSN">1460-2156</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2010-11">2010-11</date><biblScope unit="volume">133</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="3423">3423</biblScope><biblScope unit="page" to="3433">3433</biblScope></imprint><idno type="ISSN">0006-8950</idno></series><idno type="istex">E65855DBDDC436C3433EAECE51000AC6182CDE76</idno><idno type="DOI">10.1093/brain/awq212</idno><idno type="ArticleID">awq212</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8950</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">One objective of modern neuroimaging is to identify markers that can aid in diagnosis, disease progression monitoring and long-term drug impact analysis. In this study, Parkinson-associated physiopathological modifications were characterized in six subcortical structures by simultaneously measuring quantitative magnetic resonance parameters sensitive to complementary tissue characteristics (i.e. volume atrophy, iron deposition and microstructural damage). Thirty patients with Parkinsons disease and 22 control subjects underwent 3-T magnetic resonance imaging with T2-weighted, whole-brain T1-weighted and diffusion tensor imaging scans. The mean R2 value, mean diffusivity and fractional anisotropy in the pallidum, putamen, caudate nucleus, thalamus, substantia nigra and red nucleus were compared between patients with Parkinsons disease and control subjects. Comparisons were also performed using voxel-based analysis of R2, mean diffusivity and fractional anisotropy maps to determine which subregion of the basal ganglia showed the greater difference for each parameter. Averages of each subregion were then used in a logistic regression analysis. Compared with control subjects, patients with Parkinsons disease displayed significantly higher R2 values in the substantia nigra, lower fractional anisotropy values in the substantia nigra and thalamus, and higher mean diffusivity values in the thalamus. Voxel-based analyses confirmed these results and, in addition, showed a significant difference in the mean diffusivity in the striatum. The combination of three markers was sufficient to obtain a 95 global accuracy (area under the receiver operating characteristic curve) for discriminating patients with Parkinsons disease from controls. The markers comprising discriminating combinations were R2 in the substantia nigra, fractional anisotropy in the substantia nigra and mean diffusivity in the putamen or caudate nucleus. Remarkably, the predictive markers involved the nigrostriatal structures that characterize Parkinsons physiopathology. Furthermore, highly discriminating combinations included markers from three different magnetic resonance parameters (R2, mean diffusivity and fractional anisotropy). These findings demonstrate that multimodal magnetic resonance imaging of subcortical grey matter structures is useful for the evaluation of Parkinsons disease and, possibly, of other subcortical pathologies.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>Patrice Pran</name><affiliations><json:string>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</json:string><json:string>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</json:string><json:string>E-mail: p.peran@hsantalucia.it</json:string></affiliations></json:item><json:item><name>Andrea Cherubini</name><affiliations><json:string>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</json:string></affiliations></json:item><json:item><name>Francesca Assogna</name><affiliations><json:string>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</json:string></affiliations></json:item><json:item><name>Fabrizio Piras</name><affiliations><json:string>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</json:string></affiliations></json:item><json:item><name>Carlo Quattrocchi</name><affiliations><json:string>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</json:string></affiliations></json:item><json:item><name>Antonella Peppe</name><affiliations><json:string>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</json:string></affiliations></json:item><json:item><name>Pierre Celsis</name><affiliations><json:string>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</json:string></affiliations></json:item><json:item><name>Olivier Rascol</name><affiliations><json:string>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</json:string><json:string>4 Clinical Investigation Centre (INSERM CIC-9302) and Department of Neurosciences, University Hospital and University of Toulouse, France</json:string></affiliations></json:item><json:item><name>Jean-Franois Dmonet</name><affiliations><json:string>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</json:string></affiliations></json:item><json:item><name>Alessandro Stefani</name><affiliations><json:string>5 Department of Neuroscience, Tor Vergata University, Rome, Italy</json:string></affiliations></json:item><json:item><name>Mariangela Pierantozzi</name><affiliations><json:string>5 Department of Neuroscience, Tor Vergata University, Rome, Italy</json:string></affiliations></json:item><json:item><name>Francesco Ernesto Pontieri</name><affiliations><json:string>6 Sapienza University, Second Faculty of Medicine, Department of Neurology, Rome, Italy</json:string></affiliations></json:item><json:item><name>Carlo Caltagirone</name><affiliations><json:string>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</json:string></affiliations></json:item><json:item><name>Gianfranco Spalletta</name><affiliations><json:string>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</json:string></affiliations></json:item><json:item><name>Umberto Sabatini</name><affiliations><json:string>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Original Articles</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>iron</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>mean diffusivity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>anisotropy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MRI</value></json:item></subject><language><json:string>eng</json:string></language><abstract>One objective of modern neuroimaging is to identify markers that can aid in diagnosis, disease progression monitoring and long-term drug impact analysis. In this study, Parkinson-associated physiopathological modifications were characterized in six subcortical structures by simultaneously measuring quantitative magnetic resonance parameters sensitive to complementary tissue characteristics (i.e. volume atrophy, iron deposition and microstructural damage). Thirty patients with Parkinsons disease and 22 control subjects underwent 3-T magnetic resonance imaging with T2-weighted, whole-brain T1-weighted and diffusion tensor imaging scans. The mean R2 value, mean diffusivity and fractional anisotropy in the pallidum, putamen, caudate nucleus, thalamus, substantia nigra and red nucleus were compared between patients with Parkinsons disease and control subjects. Comparisons were also performed using voxel-based analysis of R2, mean diffusivity and fractional anisotropy maps to determine which subregion of the basal ganglia showed the greater difference for each parameter. Averages of each subregion were then used in a logistic regression analysis. Compared with control subjects, patients with Parkinsons disease displayed significantly higher R2 values in the substantia nigra, lower fractional anisotropy values in the substantia nigra and thalamus, and higher mean diffusivity values in the thalamus. Voxel-based analyses confirmed these results and, in addition, showed a significant difference in the mean diffusivity in the striatum. The combination of three markers was sufficient to obtain a 95 global accuracy (area under the receiver operating characteristic curve) for discriminating patients with Parkinsons disease from controls. The markers comprising discriminating combinations were R2 in the substantia nigra, fractional anisotropy in the substantia nigra and mean diffusivity in the putamen or caudate nucleus. Remarkably, the predictive markers involved the nigrostriatal structures that characterize Parkinsons physiopathology. Furthermore, highly discriminating combinations included markers from three different magnetic resonance parameters (R2, mean diffusivity and fractional anisotropy). These findings demonstrate that multimodal magnetic resonance imaging of subcortical grey matter structures is useful for the evaluation of Parkinsons disease and, possibly, of other subcortical pathologies.</abstract><qualityIndicators><score>8.5</score><pdfVersion>1.4</pdfVersion><pdfPageSize>612.68 x 790.866 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>2432</abstractCharCount><pdfWordCount>6630</pdfWordCount><pdfCharCount>45756</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>315</abstractWordCount></qualityIndicators><title>Magnetic resonance imaging markers of Parkinsons disease nigrostriatal signature</title><genre><json:string>research-article</json:string></genre><host><volume>133</volume><pages><last>3433</last><first>3423</first></pages><issn><json:string>0006-8950</json:string></issn><issue>11</issue><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1460-2156</json:string></eissn><title>Brain</title></host><categories><wos><json:string>CLINICAL NEUROLOGY</json:string><json:string>NEUROSCIENCES</json:string></wos></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1093/brain/awq212</json:string></doi><id>E65855DBDDC436C3433EAECE51000AC6182CDE76</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E65855DBDDC436C3433EAECE51000AC6182CDE76/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E65855DBDDC436C3433EAECE51000AC6182CDE76/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E65855DBDDC436C3433EAECE51000AC6182CDE76/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Magnetic resonance imaging markers of Parkinsons disease nigrostriatal signature</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability><p>OUP</p></availability><date>2010-08-23</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Magnetic resonance imaging markers of Parkinsons disease nigrostriatal signature</title><author corresp="yes"><persName><forename type="first">Patrice</forename><surname>Pran</surname></persName><email>p.peran@hsantalucia.it</email><affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</affiliation><affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</affiliation></author><author><persName><forename type="first">Andrea</forename><surname>Cherubini</surname></persName><affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</affiliation></author><author><persName><forename type="first">Francesca</forename><surname>Assogna</surname></persName><affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</affiliation></author><author><persName><forename type="first">Fabrizio</forename><surname>Piras</surname></persName><affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</affiliation></author><author><persName><forename type="first">Carlo</forename><surname>Quattrocchi</surname></persName><affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</affiliation></author><author><persName><forename type="first">Antonella</forename><surname>Peppe</surname></persName><affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</affiliation></author><author><persName><forename type="first">Pierre</forename><surname>Celsis</surname></persName><affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</affiliation></author><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</affiliation><affiliation>4 Clinical Investigation Centre (INSERM CIC-9302) and Department of Neurosciences, University Hospital and University of Toulouse, France</affiliation></author><author><persName><forename type="first">Jean-Franois</forename><surname>Dmonet</surname></persName><affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</affiliation></author><author><persName><forename type="first">Alessandro</forename><surname>Stefani</surname></persName><affiliation>5 Department of Neuroscience, Tor Vergata University, Rome, Italy</affiliation></author><author><persName><forename type="first">Mariangela</forename><surname>Pierantozzi</surname></persName><affiliation>5 Department of Neuroscience, Tor Vergata University, Rome, Italy</affiliation></author><author><persName><forename type="first">Francesco Ernesto</forename><surname>Pontieri</surname></persName><affiliation>6 Sapienza University, Second Faculty of Medicine, Department of Neurology, Rome, Italy</affiliation></author><author><persName><forename type="first">Carlo</forename><surname>Caltagirone</surname></persName><affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</affiliation></author><author><persName><forename type="first">Gianfranco</forename><surname>Spalletta</surname></persName><affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</affiliation></author><author><persName><forename type="first">Umberto</forename><surname>Sabatini</surname></persName><affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</affiliation></author></analytic><monogr><title level="j">Brain</title><idno type="pISSN">0006-8950</idno><idno type="eISSN">1460-2156</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2010-11"></date><biblScope unit="volume">133</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="3423">3423</biblScope><biblScope unit="page" to="3433">3433</biblScope></imprint></monogr><idno type="istex">E65855DBDDC436C3433EAECE51000AC6182CDE76</idno><idno type="DOI">10.1093/brain/awq212</idno><idno type="ArticleID">awq212</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010-08-23</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>One objective of modern neuroimaging is to identify markers that can aid in diagnosis, disease progression monitoring and long-term drug impact analysis. In this study, Parkinson-associated physiopathological modifications were characterized in six subcortical structures by simultaneously measuring quantitative magnetic resonance parameters sensitive to complementary tissue characteristics (i.e. volume atrophy, iron deposition and microstructural damage). Thirty patients with Parkinsons disease and 22 control subjects underwent 3-T magnetic resonance imaging with T2-weighted, whole-brain T1-weighted and diffusion tensor imaging scans. The mean R2 value, mean diffusivity and fractional anisotropy in the pallidum, putamen, caudate nucleus, thalamus, substantia nigra and red nucleus were compared between patients with Parkinsons disease and control subjects. Comparisons were also performed using voxel-based analysis of R2, mean diffusivity and fractional anisotropy maps to determine which subregion of the basal ganglia showed the greater difference for each parameter. Averages of each subregion were then used in a logistic regression analysis. Compared with control subjects, patients with Parkinsons disease displayed significantly higher R2 values in the substantia nigra, lower fractional anisotropy values in the substantia nigra and thalamus, and higher mean diffusivity values in the thalamus. Voxel-based analyses confirmed these results and, in addition, showed a significant difference in the mean diffusivity in the striatum. The combination of three markers was sufficient to obtain a 95 global accuracy (area under the receiver operating characteristic curve) for discriminating patients with Parkinsons disease from controls. The markers comprising discriminating combinations were R2 in the substantia nigra, fractional anisotropy in the substantia nigra and mean diffusivity in the putamen or caudate nucleus. Remarkably, the predictive markers involved the nigrostriatal structures that characterize Parkinsons physiopathology. Furthermore, highly discriminating combinations included markers from three different magnetic resonance parameters (R2, mean diffusivity and fractional anisotropy). These findings demonstrate that multimodal magnetic resonance imaging of subcortical grey matter structures is useful for the evaluation of Parkinsons disease and, possibly, of other subcortical pathologies.</p></abstract><textClass><keywords scheme="keyword"><list><item><term>Original Articles</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>parkinsonism</term></item><item><term>iron</term></item><item><term>mean diffusivity</term></item><item><term>anisotropy</term></item><item><term>MRI</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-08-23">Created</change><change when="2010-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E65855DBDDC436C3433EAECE51000AC6182CDE76/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">brain</journal-id><journal-id journal-id-type="publisher-id">brainj</journal-id><journal-title>Brain</journal-title><issn pub-type="ppub">0006-8950</issn><issn pub-type="epub">1460-2156</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/brain/awq212</article-id><article-id pub-id-type="publisher-id">awq212</article-id><article-categories><subj-group><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Péran</surname><given-names>Patrice</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cherubini</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Assogna</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Piras</surname><given-names>Fabrizio</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Quattrocchi</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peppe</surname><given-names>Antonella</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Celsis</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rascol</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref><xref ref-type="aff" rid="AFF4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Démonet</surname><given-names>Jean-François</given-names></name><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Stefani</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="AFF5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pierantozzi</surname><given-names>Mariangela</given-names></name><xref ref-type="aff" rid="AFF5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pontieri</surname><given-names>Francesco Ernesto</given-names></name><xref ref-type="aff" rid="AFF6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Caltagirone</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Spalletta</surname><given-names>Gianfranco</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sabatini</surname><given-names>Umberto</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib></contrib-group><aff id="AFF1">1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</aff><aff id="AFF2">2 INSERM U825, Université Paul-Sabatier, Toulouse, France</aff><aff id="AFF3">3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</aff><aff id="AFF4">4 Clinical Investigation Centre (INSERM CIC-9302) and Department of Neurosciences, University Hospital and University of Toulouse, France</aff><aff id="AFF5">5 Department of Neuroscience, Tor Vergata University, Rome, Italy</aff><aff id="AFF6">6 Sapienza University, Second Faculty of Medicine, Department of Neurology, Rome, Italy</aff><author-notes><corresp>Correspondence to: Patrice Péran, Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Via Ardeatina 306, 00179 Rome, E-mail: <email>p.peran@hsantalucia.it</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>23</day><month>8</month><year>2010</year></pub-date><volume>133</volume><issue>11</issue><fpage>3423</fpage><lpage>3433</lpage><history><date date-type="received"><day>30</day><month>3</month><year>2010</year></date><date date-type="rev-recd"><day>11</day><month>6</month><year>2010</year></date><date date-type="accepted"><day>15</day><month>6</month><year>2010</year></date></history><permissions><copyright-statement>© The Author (2010). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org</copyright-statement><copyright-year>2010</copyright-year></permissions><abstract><p>One objective of modern neuroimaging is to identify markers that can aid in diagnosis, disease progression monitoring and long-term drug impact analysis. In this study, Parkinson-associated physiopathological modifications were characterized in six subcortical structures by simultaneously measuring quantitative magnetic resonance parameters sensitive to complementary tissue characteristics (i.e. volume atrophy, iron deposition and microstructural damage). Thirty patients with Parkinson’s disease and 22 control subjects underwent 3-T magnetic resonance imaging with T<sub>2</sub>*-weighted, whole-brain T<sub>1</sub>-weighted and diffusion tensor imaging scans. The mean <italic>R</italic><sub>2</sub>* value, mean diffusivity and fractional anisotropy in the pallidum, putamen, caudate nucleus, thalamus, substantia nigra and red nucleus were compared between patients with Parkinson’s disease and control subjects. Comparisons were also performed using voxel-based analysis of <italic>R</italic><sub>2</sub>*, mean diffusivity and fractional anisotropy maps to determine which subregion of the basal ganglia showed the greater difference for each parameter. Averages of each subregion were then used in a logistic regression analysis. Compared with control subjects, patients with Parkinson’s disease displayed significantly higher <italic>R</italic><sub>2</sub>* values in the substantia nigra, lower fractional anisotropy values in the substantia nigra and thalamus, and higher mean diffusivity values in the thalamus. Voxel-based analyses confirmed these results and, in addition, showed a significant difference in the mean diffusivity in the striatum. The combination of three markers was sufficient to obtain a 95% global accuracy (area under the receiver operating characteristic curve) for discriminating patients with Parkinson’s disease from controls. The markers comprising discriminating combinations were <italic>R</italic><sub>2</sub>* in the substantia nigra, fractional anisotropy in the substantia nigra and mean diffusivity in the putamen or caudate nucleus. Remarkably, the predictive markers involved the nigrostriatal structures that characterize Parkinson’s physiopathology. Furthermore, highly discriminating combinations included markers from three different magnetic resonance parameters (<italic>R</italic><sub>2</sub>*, mean diffusivity and fractional anisotropy). These findings demonstrate that multimodal magnetic resonance imaging of subcortical grey matter structures is useful for the evaluation of Parkinson’s disease and, possibly, of other subcortical pathologies.</p></abstract><kwd-group><kwd>parkinsonism</kwd><kwd>iron</kwd><kwd>mean diffusivity</kwd><kwd>anisotropy</kwd><kwd>MRI</kwd></kwd-group></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Magnetic resonance imaging markers of Parkinsons disease nigrostriatal signature</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Magnetic resonance imaging markers of Parkinsons disease nigrostriatal signature</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Patrice</namePart><namePart type="family">Pran</namePart><affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</affiliation><affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</affiliation><affiliation>E-mail: p.peran@hsantalucia.it</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrea</namePart><namePart type="family">Cherubini</namePart><affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Francesca</namePart><namePart type="family">Assogna</namePart><affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabrizio</namePart><namePart type="family">Piras</namePart><affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Carlo</namePart><namePart type="family">Quattrocchi</namePart><affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Antonella</namePart><namePart type="family">Peppe</namePart><affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Celsis</namePart><affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</affiliation><affiliation>4 Clinical Investigation Centre (INSERM CIC-9302) and Department of Neurosciences, University Hospital and University of Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean-Franois</namePart><namePart type="family">Dmonet</namePart><affiliation>2 INSERM U825, Universit Paul-Sabatier, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alessandro</namePart><namePart type="family">Stefani</namePart><affiliation>5 Department of Neuroscience, Tor Vergata University, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mariangela</namePart><namePart type="family">Pierantozzi</namePart><affiliation>5 Department of Neuroscience, Tor Vergata University, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Francesco Ernesto</namePart><namePart type="family">Pontieri</namePart><affiliation>6 Sapienza University, Second Faculty of Medicine, Department of Neurology, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Carlo</namePart><namePart type="family">Caltagirone</namePart><affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gianfranco</namePart><namePart type="family">Spalletta</namePart><affiliation>3 Laboratory of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Umberto</namePart><namePart type="family">Sabatini</namePart><affiliation>1 Department of Radiology, I.R.C.C.S. Foundation Santa Lucia, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><subject><topic>Original Articles</topic></subject><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">2010-11</dateIssued><dateCreated encoding="w3cdtf">2010-08-23</dateCreated><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>One objective of modern neuroimaging is to identify markers that can aid in diagnosis, disease progression monitoring and long-term drug impact analysis. In this study, Parkinson-associated physiopathological modifications were characterized in six subcortical structures by simultaneously measuring quantitative magnetic resonance parameters sensitive to complementary tissue characteristics (i.e. volume atrophy, iron deposition and microstructural damage). Thirty patients with Parkinsons disease and 22 control subjects underwent 3-T magnetic resonance imaging with T2-weighted, whole-brain T1-weighted and diffusion tensor imaging scans. The mean R2 value, mean diffusivity and fractional anisotropy in the pallidum, putamen, caudate nucleus, thalamus, substantia nigra and red nucleus were compared between patients with Parkinsons disease and control subjects. Comparisons were also performed using voxel-based analysis of R2, mean diffusivity and fractional anisotropy maps to determine which subregion of the basal ganglia showed the greater difference for each parameter. Averages of each subregion were then used in a logistic regression analysis. Compared with control subjects, patients with Parkinsons disease displayed significantly higher R2 values in the substantia nigra, lower fractional anisotropy values in the substantia nigra and thalamus, and higher mean diffusivity values in the thalamus. Voxel-based analyses confirmed these results and, in addition, showed a significant difference in the mean diffusivity in the striatum. The combination of three markers was sufficient to obtain a 95 global accuracy (area under the receiver operating characteristic curve) for discriminating patients with Parkinsons disease from controls. The markers comprising discriminating combinations were R2 in the substantia nigra, fractional anisotropy in the substantia nigra and mean diffusivity in the putamen or caudate nucleus. Remarkably, the predictive markers involved the nigrostriatal structures that characterize Parkinsons physiopathology. Furthermore, highly discriminating combinations included markers from three different magnetic resonance parameters (R2, mean diffusivity and fractional anisotropy). These findings demonstrate that multimodal magnetic resonance imaging of subcortical grey matter structures is useful for the evaluation of Parkinsons disease and, possibly, of other subcortical pathologies.</abstract><subject><genre>Keywords</genre><topic>parkinsonism</topic><topic>iron</topic><topic>mean diffusivity</topic><topic>anisotropy</topic><topic>MRI</topic></subject><relatedItem type="host"><titleInfo><title>Brain</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0006-8950</identifier><identifier type="eISSN">1460-2156</identifier><identifier type="PublisherID">brainj</identifier><identifier type="PublisherID-hwp">brain</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>133</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>3423</start><end>3433</end></extent></part></relatedItem><identifier type="istex">E65855DBDDC436C3433EAECE51000AC6182CDE76</identifier><identifier type="DOI">10.1093/brain/awq212</identifier><identifier type="ArticleID">awq212</identifier><accessCondition type="use and reproduction" contentType="copyright">The Author (2010). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><covers><json:item><original>true</original><mimetype>image/tiff</mimetype><extension>tiff</extension><uri>https://api.istex.fr/document/E65855DBDDC436C3433EAECE51000AC6182CDE76/covers/tiff</uri></json:item><json:item><original>true</original><mimetype>text/html</mimetype><extension>html</extension><uri>https://api.istex.fr/document/E65855DBDDC436C3433EAECE51000AC6182CDE76/covers/html</uri></json:item></covers><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/E65855DBDDC436C3433EAECE51000AC6182CDE76/annexes/jpeg</uri></json:item><json:item><original>true</original><mimetype>image/gif</mimetype><extension>gif</extension><uri>https://api.istex.fr/document/E65855DBDDC436C3433EAECE51000AC6182CDE76/annexes/gif</uri></json:item><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E65855DBDDC436C3433EAECE51000AC6182CDE76/annexes/pdf</uri></json:item></annexes><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/E65855DBDDC436C3433EAECE51000AC6182CDE76/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">CLINICAL NEUROLOGY</classCode><classCode scheme="WOS">NEUROSCIENCES</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000102 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000102 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:E65855DBDDC436C3433EAECE51000AC6182CDE76
|texte= Magnetic resonance imaging markers of Parkinsons disease nigrostriatal signature
}}
| This area was generated with Dilib version V0.6.23. |  |